Literature DB >> 21928024

Congenital hydrocephalus associated with myeloschisis.

Yasser Jeelani1, J Gordon McComb.   

Abstract

BACKGROUND: Neural tube defects (NTDs) can be divided into two main groups, one being open NTDs wherein visible neural tissue and cerebrospinal fluid leakage are present and the other, closed NTDs without exposed neural tissue and no drainage of CSF.
METHODS: This communication is devoted to open NTDs that can be further subdivided into myelomeningoceles, myeloschisis, and hemimyelomeningoceles.
RESULTS: Common to all these is the loss of CSF during fetal development that leads to an extensive malformation of the central nervous system with hydrocephalus being a frequent feature.
CONCLUSION: The only known difference between a newborn with myelomeningocele versus a newborn with myeloschisis is the initial presence (myelomeningocele) or absence (myeloschisis) of a cystic component with the overall clinical picture the same for these two forms of open neural tube defects.

Entities:  

Mesh:

Year:  2011        PMID: 21928024     DOI: 10.1007/s00381-011-1560-4

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  12 in total

1.  The timing of primary neurosurgical repair significantly affects neurogenic bladder prognosis in children with myelomeningocele.

Authors:  Tufan Tarcan; Fikret Fatih Onol; Yalçin Ilker; Harika Alpay; Ferruh Simşek; Memet Ozek
Journal:  J Urol       Date:  2006-09       Impact factor: 7.450

Review 2.  The cause of Chiari II malformation: a unified theory.

Authors:  D G McLone; P A Knepper
Journal:  Pediatr Neurosci       Date:  1989

3.  Comparison of simultaneous versus delayed ventriculoperitoneal shunt insertion in children undergoing myelomeningocele repair.

Authors:  P D Miller; I F Pollack; D Pang; A L Albright
Journal:  J Child Neurol       Date:  1996-09       Impact factor: 1.987

Review 4.  Care of the neonate with a myelomeningocele.

Authors:  D G McLone
Journal:  Neurosurg Clin N Am       Date:  1998-01       Impact factor: 2.509

5.  Questioning the rationale and conduct of the management of myelomeningocele study.

Authors:  Helen Williams
Journal:  Med Hypotheses       Date:  2011-04-30       Impact factor: 1.538

6.  A randomized trial of prenatal versus postnatal repair of myelomeningocele.

Authors:  N Scott Adzick; Elizabeth A Thom; Catherine Y Spong; John W Brock; Pamela K Burrows; Mark P Johnson; Lori J Howell; Jody A Farrell; Mary E Dabrowiak; Leslie N Sutton; Nalin Gupta; Noel B Tulipan; Mary E D'Alton; Diana L Farmer
Journal:  N Engl J Med       Date:  2011-02-09       Impact factor: 91.245

Review 7.  Neurosurgical management of spina bifida: research issues.

Authors:  Robin M Bowman; David G McLone
Journal:  Dev Disabil Res Rev       Date:  2010

8.  Failure of third ventriculostomy in the treatment of aqueductal stenosis in children.

Authors:  G Cinalli; C Sainte-Rose; P Chumas; M Zerah; F Brunelle; G Lot; A Pierre-Kahn; D Renier
Journal:  J Neurosurg       Date:  1999-03       Impact factor: 5.115

Review 9.  Chiari Type II malformation: past, present, and future.

Authors:  Kevin L Stevenson
Journal:  Neurosurg Focus       Date:  2004-02-15       Impact factor: 4.047

Review 10.  Management of hydrocephalus in the patient with myelomeningocele: an argument against third ventriculostomy.

Authors:  Arthur E Marlin
Journal:  Neurosurg Focus       Date:  2004-02-15       Impact factor: 4.047

View more
  2 in total

1.  Evolution of posterior fossa and brain morphology after in utero repair of open neural tube defects assessed by MRI.

Authors:  Christin Rethmann; Ianina Scheer; Martin Meuli; Luca Mazzone; Ueli Moehrlen; Christian Johannes Kellenberger
Journal:  Eur Radiol       Date:  2017-05-12       Impact factor: 5.315

2.  Cerebral Abnormalities in Spina Bifida: A Neuropathological Study.

Authors:  Fabienne Paschereit; Kim Hannah Schindelmann; Michael Hummel; Joanna Schneider; Gisela Stoltenburg-Didinger; Angela M Kaindl
Journal:  Pediatr Dev Pathol       Date:  2021-10-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.